NFE2L2 and diabetes mellitus: Bach1, a known competitor of EpRE binding [49,50], was unchanged during the diabetes progression; however, in 6-month diabetic hearts, Bach1 transcripts increased suggesting that nuclear Nrf2′s potential to bind to the EpRE and initiate transcription of target genes during advanced diabetes may be inhibited by competition of Bach1.